Therapeutic Asset Ratings
615 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
PREDNISONE TABLETS
PI3Kδ Inhibitor
Fudan University
P1/2
CCC
(48)
Reishi Mushroom Extract
Pancreatic Cancer
Fudan University
P2/3
CCC
(48)
Tislezumab
Extranodal Nasal NK/T Cell Lymphoma
Fudan University
P1/2
CCC
(48)
Tislezumab
Lymphoma
Fudan University
P1/2
CCC
(48)
(+)-VINCRISTINE
Parsaclisib
Fudan University
P1/2
CCC
(48)
(+)-VINCRISTINE
PI3Kδ Inhibitor
Fudan University
P1/2
CCC
(48)
Metformin
Elderly
Fudan University
P1/2
CC
(47)
arx788
Breast Cancer
Fudan University
P2
CC
(46)
Culmerciclib
Breast Cancer
Fudan University
P2
CC
(46)
DALPICICLIB ISETIONATE
Ovarian Cancer
Fudan University
P2
CC
(46)
Fruquintinib
Pancreatic Neoplasm
Fudan University
P2
CC
(46)
GENETICALLY-MODIFIED ONCOLYTIC TYPE 5 ADENOVIRUS WHICH SELECTIVELY REPLICATES IN TUMOR CELLS CONTAINING DYSFUNCTIONAL P53 GENE (H101)
Pancreatic Neoplasm
Fudan University
P2
CC
(46)
Hrs-4508
Breast Cancer
Fudan University
P2
CC
(46)
ibi354
Breast Cancer
Fudan University
P2
CC
(46)
Iparomlimab
Pancreatic Cancer
Fudan University
P2
CC
(46)
js207
Breast Cancer
Fudan University
P2
CC
(46)
L-Ornithine L-Aspartate
Breast Cancer
Fudan University
P2
CC
(46)
Shr-1167
Breast Cancer
Fudan University
P2
CC
(46)
Shr-1701
Prostate Cancer
Fudan University
P2
CC
(46)
Shr-4602
Breast Cancer
Fudan University
P2
CC
(46)
Shr-6209
Breast Cancer
Fudan University
P2
CC
(46)
Shr-A1904
Pancreatic Neoplasm
Fudan University
P2
CC
(46)
Shr-A2102
Pancreatic Neoplasm
Fudan University
P2
CC
(46)
tqb2868
Breast Cancer
Fudan University
P2
CC
(46)
VOLITINIB
Colorectal Cancer
Fudan University
P1/2
CC
(45)
Showing 526 to 550 of 615 assets
Previous
Page 22 of 25
Next
